An 8-week Randomized, Double Blind, Multi-center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin ( 300mg/Day ) Using A Fixed Dosing Schedule In The Treatment Of Subjects With Postherpetic Neuralgia ( Phn )

Trial Profile

An 8-week Randomized, Double Blind, Multi-center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin ( 300mg/Day ) Using A Fixed Dosing Schedule In The Treatment Of Subjects With Postherpetic Neuralgia ( Phn )

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 May 2015

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Aug 2014 Top-line results published in a Pfizer Media Release.
    • 12 Aug 2014 Primary endpoint has been met (Weekly mean pain score), according to a Pfizer media release.
    • 24 Mar 2014 Status changed from recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top